市場調査レポート

商品コード

1562466

遺伝子治療の市場規模、シェア、成長分析、タイプ別、ベクター別、治療領域別、投与経路別、デリバリー方法別、地域別 - 産業予測、2024年～2031年

Gene Therapy Market Size, Share, Growth Analysis, By Type, By vector, By therapeutic area, By route of administration, By delivery method By Region - Industry Forecast 2024-2031

出版日: 2024年09月10日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

遺伝子治療の世界市場規模は2022年に74億1,000万米ドルとなり、予測期間（2024-2031年）のCAGRは21.4%で、2023年の90億米ドルから2031年には424億6,000万米ドルに成長する見通しです。

遺伝子治療の世界市場は、分子生物学と遺伝子研究の進歩によって大きな成長を遂げています。遺伝子治療は、単に症状を治療するのではなく、疾患の根本的な原因をターゲットとして、疾患を治療または予防するために遺伝子を修正または操作することを含みます。遺伝子疾患、がん、ウイルス感染症など幅広い疾患の治療が可能なことから、市場は勢いを増しています。さらに、従来の治療法が有効でなかった希少疾患の有病率が高まっていることも、遺伝子治療ソリューションの需要を後押ししています。近年、数多くの遺伝子治療製品が規制承認を受け、治療状況の変化を示しています。市場は、ベクターの種類（ウイルス性、非ウイルス性）、用途（がん、希少疾患、心血管、神経、その他）、送達方法（in vivo、ex vivo）により区分されます。

市場概要
ウイルスベクター
- レトロウイルスベクター
- ガンマレトロウイルスベクター
- レンチウイルスベクター
- アデノ随伴ウイルスベクター
- その他のウイルスベクター
非ウイルスベクター
- オリゴヌクレオチド
- その他の非ウイルスベクター

遺伝子治療市場：治療領域別

市場概要
神経学
腫瘍学
肝臓病学
その他の治療領域

遺伝子治療市場：投与経路別

市場概要
静脈内
その他の投与経路

遺伝子治療市場：デリバリー方法別

市場概要
IN VIVO
EX VIVO

遺伝子治療市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Novartis AG（Switzerland）
Biogen Inc.（US）
Gilead Sciences, Inc.（US）
Bristol-Myers Squibb（US）
Alnylam Pharmaceuticals, Inc.（US）
Sarepta Therapeutics, Inc.（US）
Amgen, Inc.（US）
Orchard Therapeutics PLC（UK）
F. Hoffmann-La Roche AG（Switzerland）
Jazz Pharmaceuticals PLC（Ireland）
uniQure N.V.（Netherlands）
Johnson & Johnson（US）
bluebird bio, Inc.（US）
BioMarin Pharmaceutical Inc.（US）
Krystal Biotech, Inc.（US）
Shanghai Sunway Biotech Co. Ltd.（China）
Sibiono Genetech Co. Ltd.（China）
Ferring B.V.（Netherlands）
Vertex Pharmaceuticals Incorporated（US）
Pfizer, Inc.（US）

Product Code: SQMIG35H2218

Global Gene Therapy Market size was valued at USD 7.41 billion in 2022 and is poised to grow from USD 9.0 billion in 2023 to USD 42.46 billion by 2031, at a CAGR of 21.4 % during the forecast period (2024-2031).

Global gene therapy market has witnessed significant growth, driven by advances in molecular biology and genetic research. Gene therapy involves modifying or manipulating genes to treat or prevent diseases, targeting the underlying cause of the condition rather than merely treating symptoms. The market has gained momentum due to its potential to treat a wide range of diseases, including genetic disorders, cancers, and viral infections. Furthermore, the increasing prevalence of rare diseases, for which traditional therapies have been ineffective, is propelling the demand for gene therapy solutions. In recent years, numerous gene therapy products have received regulatory approvals, signaling a shift in the therapeutic landscape. The market is segmented based on vector types (viral and non-viral), applications (cancer, rare diseases, cardiovascular, neurological, and others), and delivery methods (in vivo and ex vivo).

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gene Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gene Therapy Market Segmental Analysis

Global Gene Therapy Market is segmented on the basis of type, vector, therapeutic area, route of administration, delivery mode, and region. By type, market is segmented into gene silencing, cell replacement, gene augmentation, other therapies. By vector, market is segmented into viral vectors, and non-viral vectors. By therapeutic area, market is segmented into Neurology, Oncology, Hepatology, and Other Therapeutic areas. By route of administration, market is segmented into intravenous, and other routes of administration. By delivery method, market is segmented into IN VIVO, and EX VIVO. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Gene Therapy Market

One key driver of the gene therapy market is the increasing prevalence of genetic disorders. Conditions such as cystic fibrosis, hemophilia, and muscular dystrophy, which are caused by inherited genetic mutations, have traditionally been challenging to treat effectively. Gene therapy offers a novel solution by targeting the underlying genetic defects, potentially providing long-term or permanent treatment options. As diagnostic tools like next-generation sequencing (NGS) become more accessible and widely used, the identification of genetic conditions is increasing, further driving demand for innovative treatments. The rise in newborn screening and genetic counseling has also contributed to early detection, allowing gene therapies to play a crucial role in early intervention. Additionally, with growing awareness and acceptance of precision medicine, healthcare providers are increasingly adopting gene therapy as a solution for patients with genetic disorders.

Restraints in the Global Gene Therapy Market

A major restraint for the gene therapy market is the prohibitive cost of treatment. Gene therapies like Zolgensma and Luxturna, which are approved for conditions like spinal muscular atrophy and retinal dystrophy, come with price tags reaching several million dollars per patient. These high costs limit the accessibility of such treatments, especially in regions with limited healthcare funding or underdeveloped insurance systems. The production of gene therapies involves complex and costly processes, from R&D to manufacturing and clinical trials. The reliance on viral vectors for delivery, which require specialized manufacturing facilities, adds to the financial burden. Moreover, the regulatory approval pathway for gene therapies is often lengthy and rigorous, further increasing development costs. Until costs can be reduced through advancements in technology or improved insurance coverage, the broad adoption of gene therapies will face challenges.

Market Trends of the Global Gene Therapy Market

A significant trend shaping the gene therapy market is the rise in strategic collaborations and partnerships among pharmaceutical companies, biotech firms, and research institutions. Given the complexities involved in developing gene therapies-ranging from R&D to regulatory approval-companies are joining forces to pool resources, share knowledge, and accelerate product development. Collaborations have proven successful in expediting clinical trials and gaining regulatory approvals. For example, partnerships between Novartis and Avexis or Pfizer and Spark Therapeutics have helped bring gene therapies to market more efficiently. These alliances also foster innovation in gene delivery methods, particularly viral vectors, which are crucial to the effectiveness of gene therapies. As more companies recognize the potential of shared expertise, the gene therapy market is likely to witness further collaborative efforts aimed at speeding up innovation and improving treatment accessibility.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Ecosystem of the Market
Top Investment Analysis
Key Success Factor
Degree of Competition
Technology Analysis
Value Chain Analysis
Pipeline Products Analysis
Patent Analysis
Supply Chain Analysis
Regulatory Analysis
Pricing Analysis

Gene Therapy Market by Type

Market Overview
Gene Silencing
Cell Replacement
Gene Augmentation
Other Therapies

Gene Therapy Market by Vector

Market Overview
Viral Vectors
- Retroviral Vectors
- Gamma Retroviral Vectors
- Lentiviral Vectors
- Adeno-Associated Viral Vectors
- Other Viral Vectors
Non-Viral Vectors
- Oligonucleotides
- Other Non-Viral Vectors

Gene Therapy Market by Therapeutic Area

Market Overview
Neurology
Oncology
Hepatology
Other Therapeutic Areas

Gene Therapy Market by Route of Administration

Market Overview
Intravenous
Other Routes of Administration

Gene Therapy Market by Delivery Method

Market Overview
IN VIVO
EX VIVO

Gene Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sarepta Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orchard Therapeutics PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
uniQure N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bluebird bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Krystal Biotech, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Sunway Biotech Co. Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sibiono Genetech Co. Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments